EUVIMEDEUVIMED entdecken
Crossref

Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer

Sang Yi Moon, Minkook Son, Jung-Hwan Cho, Hye In Kim, Ji Min Han, Ji Cheol Bae, Sunghwan Suh iD

Thyroid® · 2025-01 · 35 (1) · 79-86

DOI: 10.1089/thy.2024.0522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 16.01.2025. Verfasst von Sang Yi Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Fatty Liver, Metabolic Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a hepatic manifestation of metabolic syndrome. This study investigated the association between newly developed nomenclature MASLD and the risk of thyroid cancer in the Korean population.

Methods

After excluding individuals with a history of liver disease or malignancy, we analyzed a cohort of 214,502 Korean adults aged 40 years and above who participated in the National Health Screening Program from 2009 to 2010. Participants were categorized into four groups: no steatotic liver disease (SLD) without a cardiometabolic risk factor (CMRF), no SLD with at least one CMRF, MASLD, and metabolic and alcohol-related/associated liver disease (MetALD). SLD was diagnosed using a fatty liver index threshold of ≥30. The primary outcome was the diagnosis of new thyroid cancer during the follow-up period. We examined the relationship between CMRF/SLD and thyroid cancer incidence using the multivariable-adjusted Cox proportional hazards model.

Results

A total of 2761 participants (1.3%) were newly diagnosed with thyroid cancer over an average follow-up of 9.61 years. Compared with participants without CMRF and SLD, those with CMRF (hazard ratio [HR] 1.33, confidence interval [CI] 1.16–1.52), those with MASLD (HR 1.36, CI 1.17–1.58), and the MetALD group (HR 1.40, CI 1.04–1.88) exhibited a significantly higher risk of thyroid cancer. In addition, MetALD is significantly associated with thyroid cancer incidence solely in men.

Conclusions

In addition to CMRF, MASLD and MetALD were associated with a higher incidence of thyroid cancer in the Korean population. This study is the first to demonstrate the association between thyroid cancer and the CMRF-MASLD-MetALD continuum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsFatty LiverMetabolic SyndromeHumansMaleFemaleMiddle AgedRepublic of KoreaAdultIncidenceAgedRisk FactorsProportional Hazards Models

Stichwörter der Autor:innen

metabolic dysfunction-associated steatotic liver diseasemetabolic syndromesteatotic liver diseasethyroid neoplasms

Autor:innen und Institutionen

  • Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea.
  • Department of Physiology, Dong-A University College of Medicine, Busan, Republic of Korea.
  • Department of Data Sciences Convergence, Dong-A University Interdisciplinary Program, Busan, Republic of Korea.
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.

ORCID-Profile: Sunghwan Suh

Zitieren

APA

Moon, S. Y., Son, M., Cho, J. H., Kim, H. I., Han, J. M., Bae, J. C., & Suh, S. (2025). Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer. Thyroid®, 35(1), 79-86. https://doi.org/10.1089/thy.2024.0522

Vancouver

Moon SY, Son M, Cho JH, Kim HI, Han JM, Bae JC, et al. Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer. Thyroid®. 2025;35(1):79-86. doi:10.1089/thy.2024.0522

BibTeX
@article{Moon2025,
  author = {Moon, Sang Yi and Son, Minkook and Cho, Jung-Hwan and Kim, Hye In and Han, Ji Min and Bae, Ji Cheol and Suh, Sunghwan},
  title = {Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer},
  journal = {Thyroid®},
  year = {2025},
  volume = {35},
  number = {1},
  pages = {79--86},
  doi = {10.1089/thy.2024.0522}
}
Kostenlos starten →